A systematic review of available clinical evidence - Filgrastim compared with lenograstim

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 8, 2011, Pages 510-518

  Sourgens, H ^a   Lefrere F ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Cytotoxic chemotherapy; Filgrastim; Granulocyte colony stimulating factor; Lenograstim; PBPC transplantation; Peripheral blood progenitor cell

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW SUPPRESSION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL STUDY; COMPARATIVE EFFECTIVENESS; COST CONTROL; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HUMAN; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD STEM CELL; RETROSPECTIVE STUDY; SEVERE CONGENITAL NEUTROPENIA; STEM CELL MOBILIZATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG COSTS; EUROPE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; NEUTROPENIA; RECOMBINANT PROTEINS;

EID: 80052224807     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201537     Document Type: Article

References (22)

1. Höglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) - what is the difference? Med Oncol. 1998; 15: 229-233. doi:10.1007/BF02787205 PubMed
2. Martin-Christin F. Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs. 2001; 12: 185-191. doi:10.1097/00001813-200103000-00002 PubMed
3. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol. 2006; 24: 5207-5215. doi:10.1200/JCO.2006.06.1663 PubMed
4. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25: 3158-3167. doi:10.1200/JCO.2006.08.8823 PubMed (Pubitemid 47218066)
5. Ataergin S, Arpaci F, Turan M, Solchaga L, Cetin T, Ozturk M, Ozet A, Komurcu S, Ozturk B. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol. 2008; 83: 644-648. doi:10.1002/ajh.21206 PubMed
6. de Arriba F, Lozano ML, Ortuño F, Heras I, Moraleda JM, Vicente V. Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and nonglycosylated rG-CSF for mobilizing peripheral blood progenitor cells. Br J Haematol. 1997; 96: 418-420. doi:10.1046/j.1365-2141. 1997.d01-2029.x PubMed (Pubitemid 27077383)
7. Kopf B, De Giorgi U, Vertagen B, Monti G, Molinari A, Turci D, Dazzi C, Leoni M, Tienghi A, Cariello A, Argnani M, Frassineti L, Scarpi E, Rosti G, Marangolo M. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant. 2006; 38: 407-412. doi:10.1038/sj.bmt. 1705465 PubMed (Pubitemid 44340369)
8. Bönig H, Silbermann S, Weller S, Kirschke R, Körholz D, Janssen G, Göbel U, Nürnberger W. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF) - results of a prospective randomised monocentre study. Bone Marrow Transplant. 2001; 28: 259-264. doi:10.1038/sj.bmt.1703136 PubMed (Pubitemid 32780878)
9. Hashino S, Morioka M, Irie T, Shiroshita N, Kawamura T, Suzuki S, Iwasaki H, Umehara S, Kakinoki Y, Kurosawa M, Kahata K, Izumiyama K, Kobayashi H, Onozawa M, Takahata M, Fujisawa F, Kondo T, Asaka M. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma. Int J Lab Hematol. 2008; 30: 292-299. doi:10.1111/j.1751-553X.2007.00955.X PubMed
10. Fischer JC, Frick M, Wassmuth R, Platz A, Punzel M, Wernet P. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol. 2005; 130: 740-746. doi:10.1111/j.1365-2141.2005.05678.x PubMed (Pubitemid 43906646)
11. Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006; 134: 517-525. doi:10.1111/j.1365-2141.2006. 06223.x PubMed (Pubitemid 44141718)
12. Martino M, Console G, Irrera G, Callea I, Condemi A, Dattola A, Messina G, Pontari A, Pucci G, Furlò G, Bresolin G, Iacopino P, Morabito F. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. J Clin Apher. 2005; 20: 129-136. doi:10.1002/jca.20049 PubMed
13. Hüttmann A, Schirsafi K, Seeber S, Bojko P. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. J Cancer Res Clin Oncol. 2005; 131: 152-156. PubMed doi:10.1007/s00432004-0636-x
14. Kim IH, Park SK, Suh OK, Oh JM. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Curr Med Res Opin. 2003; 19: 753-759. doi: 10.1185/030079903125002531 PubMed
15. Lefrère F, Bernard M, Audat F, Cavazzana-Calvo M, Belanger C, Hermine O, Arnulf B, Buzyn A, Varet B. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Leuk Lymphoma. 1999; 35: 501-505. doi:10.1080/10428199909169614 PubMed
16. Teschendorf C, Karaivanova D, Koldehoff M, Schmieget W, Graeven U. Lenograstim and filgrastim are equally effective for the hematopoietic recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Onkologie. 2010; 33 (Suppl 2): 140.
17. Ria R, Gasparre T, Mangialardi G, Bruno A, Iodice G, Vacca A, Dammacco F. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant. 2010; 45: 277-281. doi:10.1038/bmt.2009.150 PubMed
18. Saccardi R, Avanzi G, Bezzini R, Bosi A, Caporale R, Granziani G, et al. Mobilization of PBPC for hematological rescue: comparison between glycosylated and non-glycosylated G-CSF. Bone Marrow Transplant. 1997; 19 (Suppl 1; Abstr 43): S11.
19. Höglund M, Smedmyr B, Bengtsson M, Tötterman TH, Cour-Chabernaud V, Yver A, Simonsson B. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers - a comparative study. Eur J Haematol. 1997; 59: 177-183. doi:10.1111/j.1600-0609.1997.tb00972.x PubMed (Pubitemid 27392094)
20. Watts MJ, Addison I, Long SG, Hartley S, Warrington S, Boyce M, Linch DC. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol. 1997; 98: 474-479. doi:10.1046/j.1365-2141.1997.2393053.x PubMed (Pubitemid 27345130)
21. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006; 42: 2433-2453. doi:10.1016/j.ejca.2006.05.002 PubMed
22. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ et al. American Society of Clinical Oncology. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006; 24: 1-19. doi:10.1200/JCO.2006.06.4451 PubMed